Sign in

CYTR on NASDAQ

CytRx

Biopharmaceutical research company in Los Angeles, California, USA

CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California. The CytRx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin. Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as "red death".3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with PALISADE BIO, INC., Artiva Biotherapeutics, Inc. or Inhibikase Therapeutics, Inc., or pick any stock.

  • TickerCYTR on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersLos Angeles1
  • Websitewww.cytrx.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address11726 San Vicente Boulevard, Suite 650, Los Angeles, Ca 900495
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI549300XDBGI8PTJRSA424
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O The Prentice-Hall Corporation System, Inc., 19808 Wilmington, United States4

See how the biggest companies compare on our leaderboards

CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2018

-3299.2%Operating margin6
-5085.4%Net margin6
-62.4%Return on equity7
-$10.9MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2018

  • Research and development18¢$388.8K
  • Interest81¢$1.7M
  • Income tax0¢$800

Out of $250.0K in revenue.6 The company lost money this year.

Financial statements

Fiscal year2018
Revenue$250.0K6
Research and development$388.8K6
Operating expenses
Operating income-$8.2M6
Interest$1.7M6
Income before tax
Income tax-$8006
Net income-$12.7M6
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare CytRx with another company

Corporate structure

CytRx sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CytRx

  • CytRx Los Angeles, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CytRx reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$18.7K11 Dec 31, 2024$48.7K11 Dec 31, 2023−61.7%
Accumulated depreciation$17.7K11 Dec 31, 2024$42.0K11 Dec 31, 2023−57.9%
Property and equipment, net$99911 Dec 31, 2024$6.7K11 Dec 31, 2023−85.1%
Operating-lease assets (leased space)$31.6K11 Dec 31, 2023$216.8K11 Jan 1, 2023−85.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$759.7K11 Dec 31, 2024$2.1M11 Dec 31, 2023−63.3%

Properties, in its own words

We lease storage space in Los Angeles, California, which covers approximately 540 square feet. This lease expires in September 2025, and requires us to make monthly payments of $1,475.

Item 2 of the 10-K filed Mar 28, 2025.12

Leadership

Who has led CytRx, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven A. Kriegsman2006–2020
  2. Stephen Snowdy2022–2024

Chair

  1. Steven A. Kriegsman2014–2015

President

  1. Steven A. Kriegsman2014

Chief financial officer

  1. Matt Natalizio2006
  2. Mitchell K. Fogelman2007–2008
  3. John Y. Caloz2009–2024

Chief operating officer

  1. Eric Curtis2018
2010201520202025
Board members and other officers (23)

Former names

  • CYTRX CORPNov 7, 1995 to Sep 23, 20225

Timeline

  1. Jul 31, 20258-K Bankruptcy or receivership; Debt or obligation accelerated; Executive or director change42
  2. Jun 27, 20258-K Other events43
  3. Apr 16, 20258-K Executive or director change44
  4. Oct 9, 20248-K Shareholder vote45
  5. Jun 6, 20248-K Entered a material agreement; Ended a material agreement; Other events46
  6. Oct 12, 20238-K Executive or director change47
  7. Sep 11, 20238-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed48
  8. Jun 26, 20238-K Entered a material agreement; Completed an acquisition or sale; Other events49
  9. May 11, 20238-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure50
  10. Dec 30, 20228-K Executive or director change51
  11. Sep 23, 20228-K Bylaws or fiscal year changed; Regulation FD disclosure52
  12. Jul 27, 20228-K Shareholder vote53
  13. Jan 12, 2022New chief executive Stephen Snowdy becomes CEO13
  14. Jun 21, 2006New chief executive Steven A. Kriegsman becomes CEO14
  15. Jan 2, 1990Went public Listed on NASDAQ1

Filings

71 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 22 major events, 10 insider forms, 3 large holders, 1 private raises, 20 other. The latest 20:

  1. Jul 31, 20258-K EDGAR
  2. Jun 27, 20258-K EDGAR
  3. May 14, 202510-Q EDGAR
  4. Apr 16, 20258-K EDGAR
  5. Mar 28, 202510-K EDGAR
  6. Feb 21, 2025SEC STAFF ACTION EDGAR
  7. Nov 14, 202410-Q EDGAR
  8. Oct 9, 20248-K EDGAR
  9. Aug 20, 2024DEFA14A EDGAR
  10. Aug 20, 2024DEF 14A EDGAR
  11. Aug 14, 202410-Q EDGAR
  12. Jun 6, 20248-K EDGAR
  13. May 15, 202410-Q EDGAR
  14. Mar 27, 202410-K EDGAR
  15. Feb 14, 2024SC 13G/A EDGAR
  16. Jan 29, 20244 EDGAR
  17. Jan 29, 20244 EDGAR
  18. Jan 29, 20244 EDGAR
  19. Jan 29, 20244 EDGAR
  20. Jan 29, 20244 EDGAR

The 71 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 13, 2021Raised $8.2 million in a private offering of equity Form D: $18.2 million offered in all Form D

SEC filer profile

How CytRx is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLadRx Corp2
  • CIK0000799698
  • Employer ID (EIN)58-164274012
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company12
  • Incorporated inDelaware12
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address11726 San Vicente Boulevard, Suite 650, Los Angeles, CA 900492
  • Phone310-826-56482
  • Shares outstanding495,092 as of May 14, 202510
  • Public float$1.3M as of Jun 30, 202412
  • AuditorWeinberg & Company, P.A., Los Angeles, California PCAOB ID 572; no auditor attestation of internal control over financial reporting12
  • On EDGAR sinceOct 30, 19952
  • Filings1,025 in all: 8-K (263), 4 (215), 10-Q (89), DEF 14A (31), 3 (29), 424B3 (25), SC 13G/A (25), 10-K (24)2
    All 57 form types

    UPLOAD (22), S-3 (21), DEFA14A (20), EFFECT (19), 8-K/A (18), SC 13G (18), CORRESP (16), S-3/A (16), 424B5 (14), PRE 14A (14), 10-Q/A (12), 4/A (11), POS AM (11), S-8 (9), S-1/A (7), 10-K/A (6), 10-K405 (6), 424B2 (6), DFAN14A (6), 425 (5), 8-A12G/A (5), REGDEX (5), S-1 (5), 10-K405/A (4), 11-K (4), NT 10-K (4), 3/A (3), 8-A12G (3), NT 10-Q (3), PREC14A (3), PRRN14A (3), SC 13D (3), 10-C (2), ARS (2), CT ORDER (2), D (2), PREM14A (2), 25-NSE (1), D/A (1), DEFC14A (1), DEFM14A (1), DEFN14A (1), DEFS14A (1), PRES14A (1), S-3MEF (1), S-4 (1), S-4/A (1), SC 13D/A (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2025
    Quarterly report (10-Q) May 14, 2025
    Proxy statement (DEF 14A) Aug 20, 2024
    Latest 8-K (8-K) Jul 31, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par value per shareLADX
Series B Junior Participating Preferred Stock Purchase Rights

From the cover page of the 10-K filed Mar 28, 2025 (Section 12(b) of the Exchange Act).12

Risk factors and legal proceedings

The risks CytRx names in Item 1A of its 10-K filed Mar 28, 2025: 36 risks under these headings, as written.12

  • We are subject to various risks that may materially harm our business, prospects, financial condition and results of operations. An investment in our common stock is speculative and involves a high degree of risk. In evaluating an investment in our common stock, you should carefully consider the risks described below, together with the other information included in this Form 10-K, including the financial statements and related notes thereto.
  • Risks Associated With Our Business
  • We have operated at a loss and will likely continue to operate at a loss for the foreseeable future.
  • Because we have no source of significant recurring revenue, we must depend on capital raising to sustain our operations, and our ability to raise capital may be severely limited.
  • Risks Associated With Drug Discovery and Development
  • If the projected development goals for our product candidates are not achieved in the expected time frames, the commercialization of our products may be delayed and our business prospects may suffer. Our financial projections also may prove to be materially inaccurate.
  • The regulatory approval process is lengthy, time-consuming and inherently unpredictable, and if our products or those we have sold or licensed are not successfully developed and approved by the FDA or foreign regulatory authorities, we may be forced to reduce or curtail our operations.
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
  • We may be unable to protect our intellectual property rights, which could adversely affect our ability to compete effectively.
  • If our product candidates infringe or otherwise violate the rights of others, we could be subject to expensive litigation or be required to obtain licenses from others to develop or market them.
  • Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case of non-compliance with these requirements.
  • If we fail to comply with our obligations under our license agreements, we could lose the rights to intellectual property that is important to our business.
The other 26 risks
  • We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • The results of pre-clinical studies or early clinical trials are not necessarily predictive of future results, and our ultra-high potency albumin-binding drug conjugates may not have favorable results in later clinical trials or receive regulatory approval.
  • The successful commercialization of our product candidates that are approved for marketing in the United States, if any, and/or any other products that we or our partners may commercialize in the future will likely depend, in-part, on the coverage and reimbursement policies of third-party payors, which, if unfavorable, could have a material adverse effect on our business.
  • Any products that we develop or are sold or licensed may become subject to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, which could have a material adverse effect on our business.
  • Healthcare legislative reform measures could hinder or prevent the commercial success of our products and product candidates.
  • We may also be subject to federal and state healthcare laws and regulations relating to our current and/or future operations, and our failure to comply with those laws could adversely affect our business, operations and financial condition.
  • In the event of a dispute regarding our international drug development, it may be necessary for us to resolve the dispute in the foreign country of dispute, where we would be faced with unfamiliar laws and procedures.
  • Drug discovery is a complex, time-consuming and expensive process, and we may not succeed in creating new product candidates.
  • General Risk Factors
  • We are subject to intense competition, and we may not compete successfully.
  • We are subject to potential liabilities from clinical testing and future product liability claims.
  • We may be unable to successfully acquire additional technologies or products. If we require additional technologies or products, our product development plans may change and the ownership interests of our shareholders could be diluted.
  • The impact and results of our exploration of any strategic alternatives are uncertain and may not be successful.
  • We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
  • Our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
  • Global, market and economic conditions may negatively impact our business, financial condition and share price.
  • We may be subject to inflationary risk
  • We may not be successful in hiring and retaining key employees, which may harm our business.
  • You may experience future dilution as a result of future equity offerings or other equity issuances.
  • Our outstanding options, warrants, convertible preferred shares, preferred investment option and the availability for resale of the underlying shares may adversely affect the trading price of our common stock.
  • We cannot assure investors that our internal controls will prevent future material weaknesses.
  • We are subject to legal actions that could adversely affect our financial condition.
  • Our anti-takeover measures may make it more difficult to change our management, or may discourage others from acquiring us, and thereby adversely affect stockholder value.
  • Our Bylaws, as amended, designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
  • We currently take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investors.
  • We may issue additional classes of preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.
  • We do not expect to pay any cash dividends on our common stock.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Legal proceedings

We are occasionally involved in legal proceedings and other matters arising from the normal course of business. On November 30, 2022, Jerald Hammann (“Hammann”) filed a complaint (the “Complaint”) against the Company, Mr. Caloz, and Mr. Kriegsman (together, “Defendants”) in the Court of Chancery of the State of Delaware, alleging various violations of a Cooperation Agreement, dated August 21, 2020, by and between the Company and Hammann. The Complaint alleges breaches of a provision limiting the Board’s ability to effect discretionary compensation and a non-disparagement provision. The Complaint further alleges a breach of a purported implied obligation that the Company disclose various internal records to Hammann. Defendants believe the Complaint is wholly without merit and have moved to dismiss the Complaint in its entirety. Defendants intend to litigate vigorously against Hammann’s claims.

We intend to vigorously defend against any complaint. We have directors’ and officers’ liability insurance, which will be utilized, after the deductible, in the defense of any matter involving our directors or officers.

We evaluate developments in legal proceedings and other matters on a quarterly basis. If an unfavorable outcome becomes probable and reasonably estimable, we could incur charges that could have a material adverse impact on our financial condition and results of operations for the period in which the outcome becomes probable and reasonably estimable.

The opening of Item 3, Legal Proceedings.12

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
    SEC EDGAROther events
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54